NO20023036L - Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer - Google Patents

Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer

Info

Publication number
NO20023036L
NO20023036L NO20023036A NO20023036A NO20023036L NO 20023036 L NO20023036 L NO 20023036L NO 20023036 A NO20023036 A NO 20023036A NO 20023036 A NO20023036 A NO 20023036A NO 20023036 L NO20023036 L NO 20023036L
Authority
NO
Norway
Prior art keywords
protein
src
modified
inhibitors
yes
Prior art date
Application number
NO20023036A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023036D0 (no
Inventor
David A Cheresh
Brian Eliceiri
Robert Paul
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/470,881 external-priority patent/US6685938B1/en
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO20023036D0 publication Critical patent/NO20023036D0/no
Publication of NO20023036L publication Critical patent/NO20023036L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Husbandry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20023036A 1999-12-22 2002-06-21 Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer NO20023036L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/470,881 US6685938B1 (en) 1998-05-29 1999-12-22 Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A 2000-03-29 2000-03-29
PCT/US2000/035396 WO2001045751A1 (en) 1999-12-22 2000-12-22 Angiogenesis and vascular permeability modulators and inhibitors

Publications (2)

Publication Number Publication Date
NO20023036D0 NO20023036D0 (no) 2002-06-21
NO20023036L true NO20023036L (no) 2002-07-22

Family

ID=27043259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023036A NO20023036L (no) 1999-12-22 2002-06-21 Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer

Country Status (19)

Country Link
EP (2) EP1905457B1 (pt)
JP (1) JP2003518077A (pt)
KR (1) KR100813818B1 (pt)
CN (1) CN1434727A (pt)
AT (2) ATE392215T1 (pt)
AU (1) AU781444B2 (pt)
BR (1) BR0016547A (pt)
CA (1) CA2395136A1 (pt)
CZ (1) CZ304320B6 (pt)
DE (1) DE60038631T2 (pt)
DK (2) DK1250155T3 (pt)
ES (2) ES2383763T3 (pt)
HU (1) HU229628B1 (pt)
NO (1) NO20023036L (pt)
PL (1) PL356815A1 (pt)
PT (2) PT1905457E (pt)
RU (1) RU2271216C2 (pt)
SK (1) SK287575B6 (pt)
WO (1) WO2001045751A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
EP1315732B1 (en) 2000-08-25 2006-06-07 Sloan-Kettering Institute For Cancer Research Radicicol and monocillin and their analogues and uses thereof
JP2006507021A (ja) * 2002-03-18 2006-03-02 メドトロニック・エイヴイイー・インコーポレーテッド 再狭窄の危険のある解剖学的部位へ抗増殖性組成物を送付するための医療用具
WO2004006947A1 (en) * 2002-07-12 2004-01-22 Yihai Cao A method for inhibiting vascular permeability and tissue edema
EP1413887A1 (en) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Inhibitors of Src kinase for use in Alzheimer's disease
AU2003295268A1 (en) * 2002-12-19 2004-07-14 To-Bbb Holding B.V. Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
JP5520433B2 (ja) * 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US20070148225A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2463295A1 (en) * 2006-05-22 2012-06-13 The Regents of The University of California Compositions and methods for the delivery of oxygen
ATE417274T1 (de) * 2006-06-01 2008-12-15 Cellzome Ag Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
US8889840B2 (en) * 2009-10-29 2014-11-18 Industry-Academic Cooperation Foundation, Yonsei University Vascular leakage inhibitor
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
WO2014152122A2 (en) * 2013-03-15 2014-09-25 Children's Medical Center Corporation Methods of altering vascular permeability and uses thereof
CN105288654B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用
CN105311645B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
ATE120860T1 (de) * 1990-01-26 1995-04-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
US5202352A (en) 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
JP2001518502A (ja) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト チロシンキナーゼ活性を阻害するためのインデノ［１，２−ｃ］ピラゾール誘導体
ATE506073T1 (de) * 1998-05-29 2011-05-15 Scripps Research Inst Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
PL348163A1 (en) * 1998-11-06 2002-05-06 Basf Ag Inhibition of the formation of vascular hyperpermeability

Also Published As

Publication number Publication date
PT1250155E (pt) 2008-06-06
DE60038631D1 (de) 2008-05-29
AU2740001A (en) 2001-07-03
DE60038631T2 (de) 2009-06-10
EP1250155A1 (en) 2002-10-23
EP1905457A1 (en) 2008-04-02
PL356815A1 (en) 2004-07-12
ES2383763T3 (es) 2012-06-26
ES2303514T3 (es) 2008-08-16
AU781444B2 (en) 2005-05-26
RU2002119399A (ru) 2004-02-27
SK287575B6 (sk) 2011-03-04
CN1434727A (zh) 2003-08-06
DK1250155T3 (da) 2008-08-25
ATE553782T1 (de) 2012-05-15
ATE392215T1 (de) 2008-05-15
EP1250155B1 (en) 2008-04-16
DK1905457T3 (da) 2012-05-29
CA2395136A1 (en) 2001-06-28
PT1905457E (pt) 2012-05-25
HUP0203957A2 (hu) 2003-03-28
KR100813818B1 (ko) 2008-03-17
EP1905457B1 (en) 2012-04-18
RU2271216C2 (ru) 2006-03-10
JP2003518077A (ja) 2003-06-03
KR20020063259A (ko) 2002-08-01
CZ304320B6 (cs) 2014-03-05
WO2001045751A1 (en) 2001-06-28
EP1250155A4 (en) 2003-08-20
BR0016547A (pt) 2002-10-29
NO20023036D0 (no) 2002-06-21
HUP0203957A3 (en) 2005-07-28
HU229628B1 (en) 2014-03-28
SK8492002A3 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
NO20023036D0 (no) Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer
DK1638941T3 (da) Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
WO2002057259A3 (en) Pyrazole compounds useful as protein kinase inhibitors
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
CY1108041T1 (el) Αναστολεις της rho-κινασης
WO2002076976A3 (en) Rho-kinase inhibitors
ATE554087T1 (de) Neue kinaseinhibitoren
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
NO20002408L (no) 5-HT1F antagonister
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE281455T1 (de) Oxindolderivate
ATE314070T1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
DE60311284D1 (de) 4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv
DE50105650D1 (de) Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application